US Charges Chinese Nationals With Nvidia Chips Export Breach
The defendants used a company based in El Monte, California, to export sensitive technology, including graphics processing units, used in artificial intelligence without obtaining the necessary government licenses, the Justice Department said in a statement Tuesday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Equities Rise Intraday Amid Latest Corporate Results; Apple Gains
US benchmark equity indexes were higher intraday as Wall Street parsed the latest batch of earnings. Sign in to access your portfolio
Yahoo
21 minutes ago
- Yahoo
Radiant Signs Agreement Designed to Deliver Nuclear Microreactor to U.S. Military Base in 2028
First-ever deal for mass-manufactured nuclear microreactor signed with Defense Innovation Unit, Department of the Air Force EL SEGUNDO, CA / / August 6, 2025 / Radiant, the company pioneering the world's first portable, mass-produced nuclear microreactor, announced today it has signed an agreement with the Defense Innovation Unit (DIU) and the Department of the Air Force, under the Advanced Nuclear Power for Installations (ANPI) program. This is the first-ever agreement designed to deliver a mass-manufactured nuclear microreactor to a U.S. military base. This contract comes just weeks after the Department of Energy selected Radiant's Kaleidos reactor to be scheduled to test next year at Idaho National Laboratory's Demonstration of Microreactor Experiments (DOME) facility. This will be the first new design of a U.S. reactor to be tested at DOME in almost 50 years. "We're proud to be the first agreement designed to deliver mass-manufactured nuclear microreactors for a U.S. military base," said Radiant CEO and Founder Doug Bernauer. "In 36 months, Kaleidos reactors will arrive via truck and within 48 hours plug in, power on, and provide resilient, cyber-secure power to our nation's Air Force for years without refueling." DIU's mandate is to strengthen our national security by accelerating the adoption of dual-use technology for our military. DIU and the service components are collaborating on ANPI, a disciplined competition to field the nation's best microreactors, rewarding designs that prioritize safety, scalability, and the warfighter's needs. By leading on this novel capability, the Pentagon is capitalizing on this resilient, safe, and secure technology - one that will harden military bases at home and abroad and provide a decisive advantage over America's near-peer adversaries. Radiant is eager to continue to work with DIU, Department of Defense leadership, Congress, and the President to deliver Kaleidos to the Air Force within three years. For more information on Radiant and the Kaleidos microreactor, visit About Radiant Radiant is building the world's first mass-produced nuclear microreactors that can go anywhere they're needed, whenever they're needed and without constant refueling. The company's first reactor, Kaleidos, is a 1 MW failsafe microreactor that can be transported anywhere power is needed. Founded in 2020, Radiant plans to test its first reactor in 2026, with initial customer deployments beginning in 2028. Radiant's mission is to mass produce the most economical and reliable portable reactors. Contact For media inquiries, contact Ray Wert at press@ Contact Information Ray Wertpress@ SOURCE: Radiant Industries, Incorporated View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Chai Discovery Announces $70 million Series A To Transform Molecular Design
Fundraise follows foundation model breakthrough in fully de novo antibody design with the Chai-2 series of models Menlo Ventures-led round takes total funding to $100M Former Pfizer Chief Scientific Officer Mikael Dolsten, M.D., PhD., joins board SAN FRANCISCO, August 06, 2025--(BUSINESS WIRE)--Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules to accelerate life-changing therapeutics, today announced its $70 million Series A financing round. The fundraise was led by Menlo Ventures, including investment from their Anthology Fund, a joint partnership with Anthropic to identify and back promising AI companies, with participation from new investors Yosemite, DST Global Partners, SV Angel, Avenir, DCVC, and others. It also included existing investors Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, and Fred Ehrsam, among others. "Progress towards game-changing drugs and treatments is far too slow, stymied by costly trial-and-error experiments," said Joshua Meier, CEO and co-founder. "Chai Discovery exists to push the boundaries of what's possible in this field, applying frontier AI to transform biology from science to engineering, so that breakthroughs can be designed rather than simply discovered." Chai was founded in 2024 by Joshua Meier (ex AI drug discovery firm Absci; Facebook AI; OpenAI), Jack Dent (ex Eng and Product leader at Stripe), and AI researchers Matthew McPartlon and Jacques Boitreaud. Mikael Dolsten M.D., PhD., the former Pfizer Chief Scientific Officer responsible for advancing 150 molecules into clinical trials and delivering 36 approved medicines, is joining the company's board of directors. "I'm proud to join Chai Discovery and redefine biology from science into engineering," Dr. Dolsten said. "This is going to be an incredible journey with an incredible team." Last year, the company closed a $30 million seed round led by Thrive Capital, OpenAI, and Dimension. Soon after, they released Chai-1, an open-source foundation model for molecular structure prediction that performs at the state-of-the-art Last month, the team unveiled a further leap in AI-driven drug discovery with their Chai‑2 breakthrough, delivering fully de novo antibody design with a near-20% hit rate. By contrast, traditional lab based methods often have to screen millions to billions of antibodies to find hits, and the previous state of the art for computational methods was only 0.1%. When inputting only the target antigen and epitope, Chai‑2 can generate successful binders from scratch against a wide variety of targets. This means that scientists working on a target antigen, a specific disease-causing protein such as a virus or type of cancer, can use Chai-2 to design, from scratch, completely new antibodies that can hit the right spot. "Before Chai-2, the process was not unlike searching a giant bunch of keys for the right fit for a lock—but there are millions of keys," said Matthew McPartlon, co-founder. "Now, it's like having a master locksmith design exactly the right shape key, based only on your description of the lock. A company had spent more than three years and over $5m on a problem. With Chai-2, we were able to find an experimentally validated solution within two weeks." The funding will be used to further develop the Chai platform, applying it toward previously inaccessible targets, and onboarding select partners. "Chai is an exceptional technical team building foundation models for biology to transform drug discovery," said Greg Yap, Partner at Menlo Ventures. "Chai-2 demonstrates amazing progress in antibody design, and we have seen a meaningful fraction of the biotech industry already apply for Chai-2 access. At Menlo, we invest deeply in both AI foundation models and technology-enabled biology–we believe Chai can help create better medicines faster." For more information on Chai Discovery and its platform, visit About Chai Discovery Chai Discovery builds frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules, the fundamental building blocks of life. Its mission is to transform biology from science into engineering. The team hails from pioneering research and applied AI companies such as OpenAI, Meta FAIR, Stripe, and Google X, and is backed by top investors including OpenAI, Thrive Capital, Menlo Ventures and Dimension. View source version on Contacts press@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
